151 related articles for article (PubMed ID: 36166818)
1. Probing the KRas Switch II Groove by Fluorine NMR Spectroscopy.
Peacock DM; Kelly MJS; Shokat KM
ACS Chem Biol; 2022 Oct; 17(10):2710-2715. PubMed ID: 36166818
[TBL] [Abstract][Full Text] [Related]
2. Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS
Bröker J; Waterson AG; Smethurst C; Kessler D; Böttcher J; Mayer M; Gmaschitz G; Phan J; Little A; Abbott JR; Sun Q; Gmachl M; Rudolph D; Arnhof H; Rumpel K; Savarese F; Gerstberger T; Mischerikow N; Treu M; Herdeis L; Wunberg T; Gollner A; Weinstabl H; Mantoulidis A; Krämer O; McConnell DB; W Fesik S
J Med Chem; 2022 Nov; 65(21):14614-14629. PubMed ID: 36300829
[TBL] [Abstract][Full Text] [Related]
3. KRAS is vulnerable to reversible switch-II pocket engagement in cells.
Vasta JD; Peacock DM; Zheng Q; Walker JA; Zhang Z; Zimprich CA; Thomas MR; Beck MT; Binkowski BF; Corona CR; Robers MB; Shokat KM
Nat Chem Biol; 2022 Jun; 18(6):596-604. PubMed ID: 35314814
[TBL] [Abstract][Full Text] [Related]
4. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
[TBL] [Abstract][Full Text] [Related]
5. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket.
Wallon L; Khan I; Teng KW; Koide A; Zuberi M; Li J; Ketavarapu G; Traaseth NJ; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2204481119. PubMed ID: 36252024
[TBL] [Abstract][Full Text] [Related]
7. Modeling receptor flexibility in the structure-based design of KRAS
Zhu K; Li C; Wu KY; Mohr C; Li X; Lanman B
J Comput Aided Mol Des; 2022 Aug; 36(8):591-604. PubMed ID: 35930206
[TBL] [Abstract][Full Text] [Related]
8. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
9. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
[TBL] [Abstract][Full Text] [Related]
10. NMR-Chemical-Shift-Driven Protocol Reveals the Cofactor-Bound, Complete Structure of Dynamic Intermediates of the Catalytic Cycle of Oncogenic KRAS G12C Protein and the Significance of the Mg
Gadanecz M; Fazekas Z; Pálfy G; Karancsiné Menyhárd D; Perczel A
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569478
[TBL] [Abstract][Full Text] [Related]
11. A novel Imidazo[1,2-a]pyridine derivative modulates active KRAS
Ali Y; Khan AA; Alanazi AM; Fatima S; Kozmon S
Int J Biol Macromol; 2024 Jun; 270(Pt 2):132477. PubMed ID: 38772459
[TBL] [Abstract][Full Text] [Related]
12. Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile.
Zhang Z; Morstein J; Ecker AK; Guiley KZ; Shokat KM
J Am Chem Soc; 2022 Sep; 144(35):15916-15921. PubMed ID: 36001446
[No Abstract] [Full Text] [Related]
13. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
14. Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity.
Yang MH; Tran TH; Hunt B; Agnor R; Johnson CW; Shui B; Waybright TJ; Nowak JA; Stephen AG; Simanshu DK; Haigis KM
Cancer Res; 2023 Oct; 83(19):3176-3183. PubMed ID: 37556505
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
Mazhab-Jafari MT; Marshall CB; Smith MJ; Gasmi-Seabrook GM; Stathopulos PB; Inagaki F; Kay LE; Neel BG; Ikura M
Proc Natl Acad Sci U S A; 2015 May; 112(21):6625-30. PubMed ID: 25941399
[TBL] [Abstract][Full Text] [Related]
16. Real-time monitoring of the reaction of KRAS G12C mutant specific covalent inhibitor by in vitro and in-cell NMR spectroscopy.
Zhao Q; Haga R; Tamura S; Shimada I; Nishida N
Sci Rep; 2023 Nov; 13(1):19253. PubMed ID: 37935773
[TBL] [Abstract][Full Text] [Related]
17. High-resolution three-dimensional NMR structure of the
Kerkour A; Marquevielle J; Ivashchenko S; Yatsunyk LA; Mergny JL; Salgado GF
J Biol Chem; 2017 May; 292(19):8082-8091. PubMed ID: 28330874
[TBL] [Abstract][Full Text] [Related]
18. KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry.
Lu J; Harrison RA; Li L; Zeng M; Gondi S; Scott D; Gray NS; Engen JR; Westover KD
Structure; 2017 Sep; 25(9):1442-1448.e3. PubMed ID: 28781083
[TBL] [Abstract][Full Text] [Related]
19. The Research Progress of Direct KRAS G12C Mutation Inhibitors.
Yang A; Li M; Fang M
Pathol Oncol Res; 2021; 27():631095. PubMed ID: 34257597
[No Abstract] [Full Text] [Related]
20. Reduced dynamic complexity allows structure elucidation of an excited state of KRAS
Chao FA; Chan AH; Dharmaiah S; Schwieters CD; Tran TH; Taylor T; Ramakrishnan N; Esposito D; Nissley DV; McCormick F; Simanshu DK; Cornilescu G
Commun Biol; 2023 Jun; 6(1):594. PubMed ID: 37268708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
